Rules and regulations may change as more research results emerge
Second, many patients using GHK-Cu are also using it alongside GLP-1s, peptide combinations, or NAD protocols
enthusiasm dramatically outpaces science FDA Category 2 classifications for peptides like Semax reflect absence of FDA-standard evidence, not documented harmsRussian clinical experience suggests reasonable safety, but long-term effects by Western standards remain uncharacterized Established interventionsexercise, Mediterranean diet, sleep optimization, cardiovascular risk management, cognitive engagementhave far more consistent evidence than any peptide for dementia risk reduction For Research Prioritization Compounds meriting continued investigation: GLP-1 Agonists: Prevention trials in preclinical/presymptomatic populations, testing compounds with better brain penetration (dulaglutide, lixisenatide) SS-31/Elamipretide: Cognitive outcomes in mitochondrial disease populations, potential expansion to brain aging indications P21: Phase I human trials to establish safety, pharmacokinetics, and proof-of-mechanism for CNTF-pathway neurogenesis Klotho: Watch for Phase 1 results from Jocasta Neuroscience (expected 2027-2028)
Dose increase protocol (every 4 weeks) One week before your planned dose increase, ensure you have adequate medication for the new dose level
These results show that while the model performs adequately on many tautomeric pairs, further work is needed to improve consistency across challenging cases, whether a site is not identified or when tautomerism can cause large discrepancies in pKa prediction between tautomers
Phenolic compounds from the bark of Oroxylum indicum activate the Ngn2 promoter
